MoneyWorks4Me

Skybiotech Healthcare Ltd (512036)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 512036 NSE: Textile | Small Cap | Skybiotech Healthcar Share Price

₹115.05 0.05 (0.04%)

As on 22-Sep'26 16:59

Skybiotech Healthcare Ltd (512036)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 512036 NSE: Textile | Small Cap | Skybiotech Healthcar Share Price

₹115.05 0.05 (0.04%)

As on 22-Sep'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹22 Cr.
Current Price
₹115.1
52-Week Low / High
₹115 / 220
TTM EPS
₹-8.7
TTM Sales
₹5.2 Cr.
Book Value per Share
₹38.8
P/E Ratio
0.00
Lower than its 3-year historical median
Industry PE
35.8
Price to Book (P/B)
2.97
Higher than its 5-year historical median
Price to Sales (P/S)
4.23
EV/EBITDA
-17.85
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
-26.36%
Underperforms industry median
Return on Capital Employed (ROCE)
-14.91%
Underperforms industry median
Return on Assets (ROA)
-12.35%
Operating Profit Margin
-32%
Net Profit Margin
-33.59%
Gross Profit Margin
-26.7%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
-
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
63.48%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹6 Cr.
Equity
₹1.9 Cr.
Face Value
₹10
All Time Low / High
₹19.05 / 350.80

Skybiotech Healthcare stock performance

Key Ratios
mw4me loader

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Skybiotech Healthcare Ltd a good quality company?
Skybiotech Healthcare Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Skybiotech Healthcare Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Skybiotech Healthcare Ltd vs industry peers?
Skybiotech Healthcare Ltd revenue CAGR is %, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Q.1 Promoter shareholding and pledge status of Skybiotech Healthcare Ltd?
Promoters hold 63.48% of the Skybiotech Healthcare Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Skybiotech Healthcare Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -2.3% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Skybiotech Healthcare Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 0.3%1%-0.1%-1%-1.5%-1.8%-1.1%-0.2%26.2%0.7%-
Value Creation
Index
-1.0-0.9-1.0-1.1-1.1-1.1-1.1-1.00.9-1.0-

Growth Parameters

Sales 00000000000
Sales YoY Gr.-NANANANANANANANANA-
Adj EPS 0.20.2-0-0.2-0.6-0.5-0.3-0.21.2-0.2-0.2
YoY Gr.--23.8%-125%NANANANANANA-113.6%-
BVPS (₹) 17.224.226.427.221.630.935.833.656.661.560.3
Adj Net
Profit
00-0-0-0.1-0.1-0-00.2-0-0
Cash Flow from Ops. -0000.1-0.61.30.6-0.4-1.30.3-
Debt/CF from Ops. 0000000000-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales NANANANA
Adj EPS -197%NANA-113.6%
BVPS15.2%23.3%19.8%8.8%
Share Price -2.3% 30% -1.4% -38.7%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
1.20.8-0.2-0.6-2.3-1.8-1-0.63.1-0.3-0.4
Op. Profit
Mgn %
0000000000NAN
Net Profit
Mgn %
0000000000-INF
Debt to
Equity
0000000000-
Working Cap
Days
00000000000
Cash Conv.
Cycle
00000000000

Valuation of Skybiotech Healthcar - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'25
Sales7.05
Operating Expenses + 9.31
Manufacturing Costs0.42
Material Costs3.62
Employee Cost 1.96
Other Costs 3.31
Operating Profit -2.25
Operating Profit Margin (%) -32.0%
Other Income + 0.38
Exceptional Items 0
Interest 0.01
Depreciation 0.54
Profit Before Tax -2.43
Tax -0.06
Profit After Tax -2.37
PAT Margin (%) -33.6%
Adjusted EPS (₹)-12.4
Dividend Payout Ratio (%)0%
PARTICULARSMar'25

Equity and Liabilities

Shareholders Fund + 8.99
Share Capital 1.92
Reserves 7.07
Debt +7.20
Long Term Debt7.01
Short Term Debt0.19
Minority Interest1.55
Trade Payables0.62
Others Liabilities 0.82
Total Liabilities 19.18

Fixed Assets

Net Fixed Assets +12.03
Gross Block21.38
Accumulated Depreciation9.36
CWIP 0
Investments 2.46
Inventories1.59
Trade Receivables0.42
Cash Equivalents -0.27
Others Assets 2.94
Total Assets 19.18
PARTICULARSMar'25
Cash Flow From Operating Activity + -1.04
PBT -2.43
Adjustment -0.09
Changes in Working Capital 1.47
Tax Paid 0
Cash Flow From Investing Activity + -9.63
Capex -0.33
Net Investments -9.49
Others 0.18
Cash Flow From Financing Activity + 1.24
Net Proceeds from Shares 0.55
Net Proceeds from Borrowing 0.70
Interest Paid -0.01
Dividend Paid 0
Others -0
Net Cash Flow -9.43
PARTICULARSMar'25
Ratios
ROE (%)-26.36
ROCE (%)-14.91
Asset Turnover Ratio0.37
PAT to CFO Conversion(x)N/A
Working Capital Days
Receivable Days22
Inventory Days82.50
Payable Days62.90

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Skybiotech Healthcare Ltd FAQs

The current trading price of Skybiotech Healthcar on 22-Sep-2026 16:59 is ₹115.0.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Sep-2026 the market cap of Skybiotech Healthcar stood at ₹22.03 Cr

The latest P/E ratio of Skybiotech Healthcar as of 21-Sep-2026 is 0.00.

The latest P/B ratio of Skybiotech Healthcar as of 21-Sep-2026 is 1.91.

The 52-week high of Skybiotech Healthcar is ₹220.0 and the 52-week low is ₹115.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Skybiotech Healthcar is ₹0.00 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Skybiotech Healthcare Ltd is a below average quality company.

The key valuation ratios of Skybiotech Healthcare Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Skybiotech Healthcare Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Skybiotech Healthcare Ltd

Kapil Cotex Ltd is a Public Limited company incorporated on October 17, 1983. It is classified as Non-govt company and is registered at Registrar of Companies, Mumbai.

Business area of the company

The company is engaged in the business of textile & its allied products. It also deals in shares & Securities, where it earned capital gains & dividend income. Further, it gives consultancy & assistance in selling the goods of foreign clients & earned brokerage/consultancy income.

You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now